Document:

Exhibit

Exhibit 10.1

LICENSE AGREEMENT
This license agreement (the “Agreement”) is made and is effective as of March 19, 2017 (the “Effective Date”) between BlueLink Pharmaceuticals, Inc. (“Licensee”) and Cerulean Pharma Inc. (“Licensor”).  Licensee and Licensor are each referred to as a “Party” and collectively referred to as the “Parties.”
BACKGROUND
Whereas, Licensor is a biopharmaceutical company, which has developed proprietary nanoparticle-drug conjugate therapeutics including CRLX101 and CRLX301 as more fully described on Exhibit A;
Whereas, pursuant to that certain Asset Purchase Agreement, by and between Licensee and Licensor, of even date herewith (the “APA”), Licensor is selling and transferring certain intellectual property rights relating to CRLX101 and CRLX301; and
Whereas, Licensee wishes to obtain a license under, and Licensor wishes grant a license under, certain Intellectual Property Rights to research, Develop and Commercialize CRLX101 and CRLX301 under the terms and conditions set forth herein.
In consideration of the respective representations, warranties, covenants, and agreements contained herein, and for other valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:
		
	1.
	Definitions

1.1    “Affiliate” means, with respect to a specified Party, any Person that directly or indirectly controls, is controlled by, or is under common control with that Party.  For the purpose of this definition, “control” or “controlled” means direct or indirect ownership of 50% or more of the shares of stock entitled to vote for the election of directors in the case of a corporation, status as a general partner in any partnership, ownership of 50% or more of the entity’s equity interest in the case of any other type of legal entity, or any other arrangement whereby the Person controls or has the right to control the board of directors or equivalent governing body of a corporation or other entity or the ability to otherwise cause the direction of the management or policies of the corporation or other entity.  The Parties acknowledge that, in the case of entities organized under the Applicable Laws of certain countries where the maximum percentage ownership permitted by Applicable Law for a foreign investor is less than 50%, that lower percentage will be substituted in the preceding sentence if the foreign investor has the power to direct the management and policies of that entity.

1.2    “Applicable Law” means any applicable national, supranational, federal, state, local, or foreign law, statute, ordinance, principle of common law, or any rule, regulation, standard, judgment, order, writ, injunction, decree, arbitration award, agency requirement, license, or permit of any Governmental Authority. 

1.3    “Commercialization” or “Commercialize” means any and all activities directed to manufacturing, marketing, promoting, distributing, importing, exporting, using, offering to sell or selling a therapeutic, diagnostic, palliative, and/or prophylactic product, as well as activities directed to obtaining pricing approvals, reimbursement and medical affairs activities, as applicable.

1.4    “Control” or “Controlled” means, with respect to any Intellectual Property Right, the possession by a Party (whether by ownership, license, or otherwise) of the ability (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) to grant access to, or a license or sublicense of, such rights or property, without violating the terms of any agreement or other arrangement with any Third Party.

1.5    “Confidential Information” means any confidential or proprietary information furnished by one Party to the other Party in connection with this Agreement, provided that such information is specifically designated as confidential.  Confidential Information includes non-public information disclosed by Licensor to Licensee relating to patent application prosecution files for the Licensed Patent Rights.

1.6    “CRLX101” means the clinical candidate Controlled by Licensor referred to as CRLX101, the chemical structure of which is set forth on Exhibit A.

Exhibit 10.1

1.7    “CRLX301” means the clinical candidate Controlled by Licensor referred to as CRLX301, the chemical structure of which is set forth on Exhibit A.
 
1.8    “Develop” or “Development” means drug development activities, including test method development and stability testing, assay development and audit development, toxicology, formulation, quality assurance/quality control development, statistical analysis, pre-clinical studies, clinical studies, packaging development, regulatory affairs, and the preparation, filing, and prosecution of regulatory applications, interactions with regulatory authorities, as well as related medical affairs, as well as manufacturing, process development, production and distribution of clinical supply materials.
 
1.9    “Discontinuation Notice” has the meaning set forth in Section 3.2.2.

1.10    “Field of Use” means all fields. 

1.11    “Indemnitee” has the meaning set forth in Section 6.3.

1.12    “Intellectual Property Rights” means Patent Rights and Know How.

1.13    “Know How” means any information, inventions, trade secrets or technology, whether or not proprietary or patentable and whether stored or transmitted in oral, documentary, electronic, or other form.  Know How will include non-patented inventions, ideas, concepts, formulas, methods, procedures, designs, compositions, plans, documents, data, discoveries, developments, techniques, protocols, specifications, works of authorship, biological materials, and any information relating to research and development plans, experiments, results, compounds, services and service protocols, clinical and preclinical data, clinical trial results, and manufacturing information and plans.

1.14    “Licensed Know How” means Know How owned or Controlled by Licensor, as such Know How exists as of the Effective Date or is otherwise delivered to Licensee after the Effective Date pursuant to the terms of the APA (other than Know How assigned by Licensor to Licensee pursuant to the APA and excluding, for the avoidance of doubt, Know How Controlled by any other Person acquiring Licensor or Intellectual Property Rights Controlled by Licensor after the Effective Date or to which this Agreement is assigned after the Effective Date), to the extent such Know How is necessary to research, Develop or Commercialize the Licensed Products.

1.15    “Licensed Patent Rights” means (a) Patent Rights Controlled by Licensor as of the Effective Date (other than Patent Rights assigned by Licensor to Licensee pursuant to the APA and excluding, for the avoidance of doubt, Patent Rights Controlled by any other Person acquiring Licensor or Intellectual Property Rights Controlled by Licensor after the Effective Date or to which this Agreement is assigned after the Effective Date), (b) Patent Rights arising therefrom (but, as to continuations-in-part, solely to the extent supported by the specifications of such Patent Rights), reissues, re-examinations, extensions, supplementary protection certificates and similar progeny of any such Patent Rights, and (c) counterparts of any of the foregoing anywhere in the world.

1.16    “Licensed Product” means any product containing CRLX101 or CRLX301.

1.17    “Patent Rights” means patents and patent applications, including any substitutions, divisionals, continuations, continuations-in-part, reissues, re-examinations, extensions, supplementary protection certificates and similar progeny of patents and patent applications, and counterparts of any of the foregoing anywhere in the world existing as of the date of this Agreement and during the term of this Agreement.

1.18    “Person” means any corporation, limited or general partnership, limited liability company, joint venture, trust, unincorporated association, governmental body, authority, bureau or agency, any other entity or body, or an individual.

1.19    “Platform Technology” means the Licensed Patent Rights, the Sublicensed Patent Rights, the Licensed Know How and the Sublicensed Know How.

1.20    “Practice” means, with respect to Patent Rights, to make, use, sell, offer for sale, or import (or have made, have used, have sold, have offered for sale, or have imported), and, with respect to Know How, to use, practice and disclose (or have used, practiced and disclosed) or assert said Patent Rights or Know How against Third Parties as such relates to the Licensed Products.

1.21    “Retained Third Party License Agreements” means the license agreements set forth on Exhibit B.

Exhibit 10.1

1.22    “Review and Comment Patent Rights” has the meaning set forth in Section 3.2.1.

1.23    “Sublicensed Know How” means the Know How Controlled by Licensor under the Retained Third Party License Agreements.

1.24    “Sublicensed Patent Rights” means the Patent Rights Controlled by Licensor under the Retained Third Party License Agreements.

1.25    “Territory” means worldwide.

1.26    “Third Party” means any Person other than Licensor or Licensee and their respective Affiliates.

1.27    “Third Party Infringement” has the meaning set forth in Section 3.1.1.

		
	2.
	License; Responsibilities.

2.1    License Grant.  
2.1.1    Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an exclusive, perpetual, sublicensable right and license, under the Platform Technology, to research, Develop and Commercialize Licensed Products in the Field of Use in the Territory.  

2.1.2    The license grant pursuant to this Section 2.1 is fully paid and royalty-free, except for any obligations under the Retained Third Party License Agreements arising from Licensee’s (or its Affiliates or sublicensees’) research, Development, and Commercialization of Licensed Products, all of which will be borne by Licensee and its sublicensees, and Licensee and its sublicensees will reimburse Licensor or its assignee of the Retained Third Party License Agreements for any payments made by Licensor or its assignee pursuant to the Retained Third Party License Agreements on behalf of Licensee and its sublicensees based on their Practice of Platform Technology.  Licensee will provide sufficient notice and information to Licensor with respect to Licensee’s activities under this license to permit Licensor or its assignee to comply with all of its obligations with respect to Licensed Products under the Retained Third Party License Agreements, including but not limited to payment and reporting obligations with respect to Licensed Products under such Retained Third Party License Agreements arising from Licensee’s research, Development, and Commercialization of CRLX101 and/or CRLX301.  

2.2    No Additional Rights.  Nothing in this Agreement shall be construed to confer any rights upon Licensee by implication, estoppel, or otherwise as to any technology or Intellectual Property Rights of Licensor or any other entity other than the Platform Technology, solely to the extent such rights are granted under Section 2.1, regardless of whether such technology or Patent Rights shall be dominant or subordinate to any Platform Technology.

2.3    Retained Third Party License Agreement Terms; Maintenance.  The sublicenses granted hereunder to Licensee under the Retained Third Party License Agreements are subject to all applicable terms of the Retained Third Party License Agreements. Licensor shall not amend, modify or waive any rights under any of the Retained Third Party License Agreements in a manner that would negatively impact the Sublicensed Patent Rights.  In addition, Licensor shall use reasonable efforts to maintain each Retained Third Party License Agreement in effect (including making any payments thereunder, subject to Licensee’s satisfaction of its reimbursement obligations to Licensor under Section 2.1.2), to notify and satisfy any consent or notification requirements to effect the sublicenses granted pursuant to this Agreement under each such Retained Third Party License Agreement and to promptly notify Licensee of any notification of breach or termination by the licensor under any of the Retained Third Party License Agreements.  If Licensor assigns this Agreement to an assignee pursuant to Section 8.3, Licensee shall use commercially reasonable efforts to negotiate with such assignee to amend the Retained Third Party License Agreements so that (i) Licensee can enter into separate agreements with respect to the research, Development and Commercialization of the Products and (ii) the Retained Third Party License Agreements are no longer necessary to allow Licensee to research, Develop and Commercialize the Products.

		
	3.
	Intellectual Property Protection and Related Matters

3.1    Enforcement.

Exhibit 10.1

3.1.1    Each Party will promptly notify the other Party (or their assignees or sublicensees)  of any infringement by a Third Party of any of the Licensed Patent Rights of which it becomes aware, including any “patent certification” filed in the United States under 21 USC §355(b)(2) or 21 USC §355(j)(2) or similar provisions in other jurisdictions, and of any request for declaratory judgment, opposition, nullity action, interference, inter-partes reexamination, inter-partes review, post-grant review, derivation proceeding, or similar action alleging the invalidity, unenforceability or non-infringement of any of such Licensed Patent Rights (collectively “Third Party Infringement”). 

3.1.2    Licensee will have the sole right to bring and control any legal action in connection with Third Party Infringement of the Licensed Patent Rights, as such relates primarily to the research, Development, and Commercialization of Licensed Products, at its own expense as it reasonably determines appropriate, and Licensor or its assignee shall have the right, at its own expense, to be represented in any such action by counsel of its own choice. 

3.1.3    Licensor or its assignee will have the sole right to bring and control any other (i.e., not set forth in Section 3.1.2) legal action in connection with Third Party infringement of the Licensed Patent Rights, at its own expense as it reasonably determines appropriate, and Licensee shall have the right, at its own expense, to be represented in any such action by counsel of its own choice.

3.1.4    At the request of a Party the other Party shall provide assistance in connection therewith, including by executing reasonably appropriate documents and, cooperating reasonably in discovery and joining as a party to the action if required.  

3.1.5    In connection with any such proceeding, neither Party nor, in the case of Licensor, Licensor’s assignee, shall enter into any settlement admitting the invalidity of, or otherwise impairing either Party’s rights in, the Licensed Patent Rights without the prior written consent of the other Party, which will not be unreasonably withheld, conditioned or delayed.  

3.1.6    Any recoveries resulting from such an action relating to a claim of Third Party Infringement shall be retained by the Person bringing the action. 

3.1.7    The rights granted to Licensee under this Section 3.1 are subject to all applicable terms of the Retained Third Party License Agreements with respect to any Sublicensed Patent Rights.

3.2    Maintenance of Patents.

3.2.1    Licensor or its assignee will have sole responsibility for (and will bear the cost of) preparing, filing, prosecuting, and maintaining any Licensed Patent Rights, in its sole discretion, with the exception that, subject to the provision(s) below, Licensor or its assignee will use commercially reasonable efforts to continue to maintain any of the Licensed Patent Rights that relate to Licensed Products.  Licensor or its assignee will provide Licensee with a reasonable opportunity to review and comment on substantive filings with respect to the Licensed Patent Rights set forth on Exhibit D (the “Review and Comment Patent Rights”), and shall use reasonable efforts to keep Licensee reasonably informed in a timely manner of progress with regard to the preparation, filing, prosecution and maintenance of the Review and Comment Patent Rights.  Licensor shall consider in good faith the requests and suggestions of Licensee with respect to strategies for filing and prosecuting Review and Comment Patent Rights.

3.2.2    If Licensor or its assignee elects to discontinue its financial support for the prosecution of a pending Licensed Patent Right or the maintenance of an issued Licensed Patent Right in one or more (or all) jurisdictions, that relate to Licensed Products, Licensor or its assignee will give prompt and timely notice (not less than 30 days) of that election (a “Discontinuation Notice”) to Licensee in sufficient time to permit the Licensee to assume the prosecution and maintenance of such patent applications or patents in such jurisdiction, and Licensee may, at its election, assume full financial responsibility for those costs and expenses in such jurisdictions. 

3.2.3    If Licensee assumes full financial responsibility for those costs and expenses in those jurisdictions, Licensor or its assignee will promptly (not more than 10 days) assign its rights to the relevant Licensed Patent Right to Licensee in those jurisdictions (for the avoidance of doubt, on a jurisdiction-by-jurisdiction basis, 

Exhibit 10.1

only where Licensor or its assignee has elected to cease its support), including the right to Practice such Licensed Patent Rights in such jurisdiction; 

3.2.4    If Licensee does not assume responsibility for the continued prosecution and/or maintenance within 30 days after the Discontinuation Notice, Licensor will have no further responsibility with respect to the prosecution or maintenance of the relevant Patent Rights.

3.2.5    The rights granted to Licensee under this Section 3.2 are subject to all applicable terms of the Retained Third Party License Agreements.

3.3    Patent Term Extension.  Subject to the applicable terms of the Retained Third Party License Agreements, Licensee shall have the right but not the obligation, to the extent allowed by Applicable Law, after it has submitted for regulatory approval of Licensed Products, to seek, in Licensor’s name if so required, patent term extensions, supplemental protection certificates and the like available under Applicable Law, including 35 U.S.C. 156 and applicable foreign counterparts, of the Licensed Patent Rights in such country in relation to Licensed Products.

		
	4.
	Confidentiality

4.1    Confidential Information.  All Confidential Information disclosed by a Party to the other Party during the term of this Agreement shall not be used by the receiving Party except in connection with the activities contemplated by this Agreement, shall be maintained in confidence by the receiving Party (except to the extent reasonably necessary for regulatory approval of Licensed Products, for the filing, prosecution and maintenance of Patent Rights or to develop and Commercialize Licensed Products in accordance with this Agreement), and shall not otherwise be disclosed by the receiving Party to any other Person, firm, or agency, governmental or private (except consultants, advisors and Affiliates in accordance with Section 4.2), without the prior written consent of the disclosing Party, except to the extent that the Confidential Information:

4.1.1    was known or used by the receiving Party prior to its date of disclosure to the receiving Party;

4.1.2    either before or after the date of the disclosure to the receiving Party is lawfully disclosed to the receiving Party by sources other than the disclosing Party rightfully in possession of the Confidential Information;

4.1.3    either before or after the date of the disclosure to the receiving Party becomes published or generally known to the public through no fault or omission on the part of the receiving Party;

4.1.4    is independently developed by or for the receiving Party without reference to or reliance upon the Confidential Information; or

4.1.5    is required to be disclosed by the receiving Party to comply with Applicable Laws or regulations, to defend or prosecute litigation or to comply with legal process, provided that the receiving Party provides prior written notice of such disclosure to the disclosing Party and only discloses Confidential Information of the other Party to the extent necessary for such legal compliance or litigation purpose.

4.2    Employee, Consultant and Advisor Obligations.  Licensee and Licensor each agrees that it and its Affiliates shall provide Confidential Information received from the other Party only to the receiving Party's respective employees, consultants and advisors, and to the employees, consultants and advisors of the receiving Party’s Affiliates, who have a need to know such Confidential Information to assist the receiving Party in fulfilling its obligations under this Agreement; provided that Licensee and Licensor shall each remain responsible for any failure by its and its Affiliates' respective employees, consultants and advisors to treat such Confidential Information as required under Section 4.1.  

4.3    Survival.  All obligations of confidentiality imposed under this Section 4 shall survive the termination or expiration of this Agreement and shall expire five (5) years following such termination or expiration.

		
	5.
	Representations and Warranties

Exhibit 10.1

5.1    Representations of Authority.  Each Party represents and warrants to the other that as of the Effective Date it has full right, power and authority to enter into this Agreement and to perform its respective obligations under this Agreement.  

5.2    Consents.  Each Party represents and warrants that as of the Effective Date all necessary consents, approvals and authorizations of all government authorities and other Persons required to be obtained by such Party in connection with execution, delivery and performance of this Agreement have been obtained.

5.3    No Conflict.  Each Party represents and warrants that, as of the Effective Date, the execution and delivery of this Agreement (a) do not conflict with or violate any requirement of Applicable Laws or regulations and (b) do not conflict with, violate or breach or constitute a default of, or require any consent under, any contractual obligations of such Party, except such consents as have been obtained as of the Effective Date.

5.4    Employee, Consultant and Advisor Obligations.  Each Party represents and warrants that, as of the Effective Date, each of its and its Affiliates' employees, consultants and advisors has executed an agreement or has an existing obligation under law obligating such employee, consultant or advisor to maintain the confidentiality of Confidential Information to the extent required under Section 4.

5.5    No Warranties.  EXCEPT AS OTHERWISE EXPRESSLY SET FORTH HEREIN, THE PARTIES MAKE NO REPRESENTATIONS AND EXTEND NO WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED.

		
	6.
	Indemnification.

6.1    By Licensee.  Licensee agrees to defend Licensor, its Affiliates and their respective directors, officers, employees, agents, successors and assigns at Licensee’s cost and expense, and shall indemnify and hold harmless Licensor and its Affiliates and their respective directors, officers, employees and agents from and against any liabilities, losses, costs, damages, fees or expenses arising out of any Third Party claim arising from (a) any breach by Licensee of any of its representations, warranties or obligations pursuant to this Agreement, or (b) the research, Development, and/or Commercialization of a Licensed Product by Licensee, its Affiliates, or their sublicensees, including satisfaction of all obligations (including but not limited to payment) under the Retained Third Party License Agreements arising from the research, Development, and/or Commercialization of a Licensed Product or the practice of the rights granted under the Retained Third Party License Agreements.

6.2    Procedures.  A person entitled to indemnification under this Section 6 (an “Indemnitee”) shall give prompt written notification to Licensee of any claim, suit, action or demand for which indemnification is sough under this Agreement.  Within thirty (30) days after delivery of such notification, Licensee may, upon written notice thereof to the Indemnitee, assume control of the defense of such claim, suit, action or demand with counsel reasonably satisfactory to the Indemnitee.  If Licensee does not assume control of such defense, the Indemnitee shall control such defense.  The Party not controlling such defense may participate therein at its own expense; provided that, if that the Indemnitee shall have the right to retain its own counsel, at the expense of Licensee, if representation of such Indemnitee by the counsel retained by Licensee would be inappropriate because of actual or potential differences in the interests of such Indemnitee and any other party represented by such counsel.  The Indemnitee shall not agree to any settlement of such action, suit, proceeding or claim without the prior written consent of Licensee, which shall not be unreasonably withheld, delayed or conditioned.

		
	7.
	Term and Termination

7.1    Term.  This Agreement shall become effective as of the Effective Date, may be terminated as set forth in this Section 7, and otherwise remains in effect in perpetuity.

7.2    Termination.  Licensee may terminate this Agreement upon sixty (60) days’ notice to Licensor for any or no reason.  Upon any material breach of this Agreement by Licensee, Licensor may terminate this Agreement by providing sixty (60) days’ written notice to Licensee, specifying the material breach.  The termination shall become effective at the end of the sixty (60) day period unless Licensee cures such breach during such sixty (60) day period. 

7.3    Survival.  The following provisions shall survive the expiration or termination of this Agreement: Sections 4, 6, 7, and 8.

		
	8.
	Miscellaneous Provisions

Exhibit 10.1

8.1    Governing Law.  This Agreement will be governed by and construed under the laws of the State of Delaware, without giving effect to the conflicts of laws provision thereof.  For the avoidance of doubt, the United Nations Convention on Contracts for the International Sale of Goods (1980) will not apply to the interpretation of this Agreement.

8.2    Notice.  Any notices required or permitted by this Agreement shall be in writing, shall specifically refer to this Agreement, and shall be sent by hand, recognized national overnight courier, confirmed facsimile transmission, confirmed electronic mail, or registered or certified mail, postage prepaid, return receipt requested, to the following address or facsimile number of the parties:

If to Licensor:
Cerulean Pharma Inc.
35 Gatehouse Drive
Waltham, MA 02451 USA
Attn: Chief Executive Officer

With a copy to: General Counsel

If to Licensee:
NewLink Genetics Corporation
2801 Via Fortuna, Suite 520
Austin, Texas 78746
Attn: General Counsel

All notices under this Agreement shall be deemed effective upon receipt.  A party may change its contact information immediately upon written notice to the other party in the manner provided in this Section.
8.3    Assignment.  This Agreement may be assigned by Licensor in connection with the sale or transfer of all or substantially all of the Platform Technology without the prior written consent of Licensee, provided that Licensor requires the acquirer to assume all of the terms of this Agreement and provides notice of such assignment and assumption to Licensee.  Either Party may assign this Agreement in connection with the sale or transfer of all or substantially all of the business and assets of such Party.  Either Party may assign its rights and obligations under this Agreement in whole or in part to an Affiliate of such Party.

8.4    Entire Agreement.  This Agreement constitutes the entire agreement between the parties with respect to its subject matter and supersedes all prior agreements or understandings between the parties relating to its subject matter.

8.5    Amendment and Waiver.  This Agreement may be amended, supplemented, or otherwise modified only by means of a written instrument signed by both parties.  Any waiver of any right or failure to act in a specific instance shall related only to such instance and shall not be construed as an agreement to waive any right or fail to act in any other instance, whether or not similar.

8.6    Severability.  Should one or more of the provisions of this Agreement become void or unenforceable as a matter of law, then this Agreement will be construed as if such provision were not contained herein and the remainder of this Agreement will be in full force and effect, and the Parties will use their commercially reasonable efforts to substitute for the invalid or unenforceable provision a valid and enforceable provision which conforms as nearly as possible with the original intent of the Parties.

8.7    LIMITATION OF LIABILITY.  OTHER THAN IN CONNECTION WITH A BREACH OF CONFIDENTIALITY, THIRD PARTY CLAIMS, OR AN INDEMNIFICATION OBLIGATION UNDER SECTION 6, NEITHER PARTY HERETO WILL BE LIABLE FOR INDIRECT, INCIDENTAL, CONSEQUENTIAL, SPECIAL, EXEMPLARY OR PUNITIVE DAMAGES ARISING OUT OF THIS AGREEMENT OR THE EXERCISE OF ITS RIGHTS HEREUNDER, OR FOR LOST PROFITS ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES.

Exhibit 10.1

8.8    Counterparts.  This Agreement may be executed in counterparts, each of which counterparts, when so executed and delivered, shall be deemed to be an original, and all of which counterparts, taken together, shall constitute one and the same instrument.

Exhibit 10.1

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first set forth above.

	
			
	BlueLink Pharmaceuticals, Inc.
	 
	Cerulean Pharma Inc.

	 
	 
	 

	 
	 
	 

	_/s/ Charles J. Link Jr.____________
	 
	_/s/ Christopher D. T. Guiffre___________ 

	Signature
	 
	Signature

	 
	 
	 

	___Charles J. Link Jr._________________
	 
	____Christopher D. T. Guiffre__________

	Printed Name
	 
	Printed Name

	 
	 
	 

	___Chief Executive Officer___________
	 
	____President & Chief Executive Officer_

	Title
	 
	Title

	 
	 
	 

Exhibit 10.1

Exhibit A - Description of Licensed Products

Products identified as CRLX101 and CRLX301 consisting generally of a CDP-based polymer covalently bound to an active pharmaceutical ingredient through a linker.

Exhibit 10.1

Exhibit B  - Retained Third Party License Agreements

Calando Product Agreement: IT-101 Agreement by and between Calando Pharmaceuticals, Inc. and the Company, effective June 23, 2009, as amended.
Calando Platform Agreement: Platform Agreement by and between Calando Pharmaceuticals, Inc. and the Company, effective June 23, 2009, as amended.
Calando/CalTech Side Letter: Letter Agreement by and between Calando Pharmaceuticals, Inc., California Institute of Technology and the Company, dated August 6, 2013.

Exhibit 10.1

Exhibit C  - [Reserved]

Exhibit 10.1

Exhibit D  - Review and Comment Patent Rights 

	
													
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 
	 

	3770286.7
	AT
	T2021-7007
	AT
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	AT
	T2021-7007
	AT1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	2009251190
	AU
	T2021-7007
	A1
	Granted
	04-Sep-2003
	2009251190
	09-Aug-2012
	2009251190
	07-Mar-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	2012247051
	AU
	T2021-7007
	A2
	Granted
	04-Sep-2003
	 
	19-Feb-2015
	2012247051
	04-Jun-2015
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	2003278764
	AU
	T2021-7007
	AU
	Granted
	04-Sep-2003
	2003278764
	04-Feb-2010
	2003278764
	09-Sep-2010
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	BE
	T2021-7007
	BE
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	BE
	T2021-7007
	BE1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	BR122012021252-0
	BR
	T2021-7007
	B1
	Published
	04-Sep-2003
	BR122012021252-0
	15-Oct-2013
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	PI0314042-3
	BR
	T2021-7007
	BR
	Published
	04-Sep-2003
	PI0314042-3
	 
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	2818071
	CA
	T2021-7007
	C1
	Granted
	04-Sep-2003
	 
	 
	2818071
	18-Aug-2015
	MODIFIED CYCLODEXTRIN RING COMPOUNDS HAVING EXACLY TWO HYDROXYL MOIETIES SUBSTITUTED WITH AN AMINO ACID FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC. 

	2497792
	CA
	T2021-7007
	CA
	Granted
	04-Sep-2003
	 
	 
	2497792
	05-Aug-2014
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

Exhibit 10.1

	
													
	03770286.7
	CH
	T2021-7007
	CH
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	CH
	T2021-7007
	CH1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	201110329366.X
	CN
	T2021-7007
	1C
	Granted
	04-Sep-2003
	102516417
	27-Jun-2012
	ZL201110329366.X
	10-Dec-2014
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	201410658743.8
	CN
	T2021-7007
	2C
	Published
	04-Sep-2003
	104383554
	04-Mar-2015
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	ZL03824829.8
	CN
	T2021-7007
	CN
	Granted
	04-Sep-2003
	1694728A
	09-Nov-2005
	ZL03824829.8
	28-Dec-2011
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	03770286.7
	CY
	T2021-7007
	CY
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	CY
	T2021-7007
	CY1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	DE
	T2021-7007
	DE
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	DE
	T2021-7007
	DE1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184901.6
	EP
	T2021-7007
	E2
	Published
	04-Sep-2003
	2402036
	04-Jan-2012
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	ES
	T2021-7007
	ES
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

Exhibit 10.1

	
													
	10184884.4
	ES
	T2021-7007
	ES1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	FR
	T2021-7007
	FR
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	FR
	T2021-7007
	FR1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	GB
	T2021-7007
	GB
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	GB
	T2021-7007
	GB1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	GR
	T2021-7007
	GR
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	GR
	T2021-7007
	GR1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	11105534.9
	HK
	T2021-7007
	H1
	Granted
	04-Sep-2003
	1151467
	03-Feb-2012
	1151467
	03-Jan-2014
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	12106119.9
	HK
	T2021-7007
	H2
	Published
	04-Sep-2003
	1165305
	05-Oct-2012
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	5104980.9
	HK
	T2021-7007
	HK
	Granted
	04-Sep-2003
	1072202
	19-Aug-2005
	1072202
	06-Jul-2012
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	IE
	T2021-7007
	IE
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

Exhibit 10.1

	
													
	10184884.4
	IE
	T2021-7007
	IE1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	167169
	IL
	T2021-7007
	IL
	Granted
	04-Sep-2003
	 
	30-Oct-2014
	167169
	31-Jan-2015
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	03770286.7
	IT
	T2021-7007
	IT
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	IT
	T2021-7007
	IT1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	2011-1566
	JP
	T2021-7007
	J1
	Granted
	04-Sep-2003
	 
	 
	5586487
	01-Aug-2014
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	2012-4159
	JP
	T2021-7007
	J2
	Granted
	04-Sep-2003
	 
	 
	5681646
	16-Jan-2015
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	2014-108845
	JP
	T2021-7007
	J3
	Granted
	04-Sep-2003
	 
	 
	5934743
	13-May-2016
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	10-2013-7006800
	KR
	T2021-7007
	K2
	Granted
	04-Sep-2003
	 
	 
	1476067
	17-Dec-2014
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	INSERT THERAPEUTICS, INC.

	10-2014-7014132
	KR
	T2021-7007
	K3
	Pending
	04-Sep-2003
	 
	 
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	INSERT THERAPEUTICS, INC.

	10-2016-7024300
	KR
	T2021-7007
	K4
	Pending
	04-Sep-2003
	 
	 
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	INSERT THERAPEUTICS, INC.

	10-2005-7003918
	KR
	T2021-7007
	KR
	Granted
	04-Sep-2003
	 
	 
	10-1268258
	21-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	INSERT THERAPEUTICS, INC.

	03770286.7
	LU
	T2021-7007
	LU
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

Exhibit 10.1

	
													
	10184884.4
	LU
	T2021-7007
	LU1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	MX/a/2011/001769
	MX
	T2021-7007
	M1
	Granted
	04-Sep-2003
	 
	 
	309331
	06-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	MX/a/2013/004590
	MX
	T2021-7007
	M2
	Pending
	24-Apr-2013
	 
	 
	 
	 
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	PA/a/2005/002444
	MX
	T2021-7007
	MX
	Granted
	04-Sep-2003
	 
	 
	299199
	15-May-2012
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	03770286.7
	NL
	T2021-7007
	NL
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	NL
	T2021-7007
	NL1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	03770286.7
	PT
	T2021-7007
	PT
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	1534340
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	PT
	T2021-7007
	PT1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	2277551
	08-May-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	2005110059
	RU
	T2021-7007
	RU
	Granted
	04-Sep-2003
	 
	 
	2332425
	########
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CALANDO PHARMACEUTICALS INC.

	200501307-3
	SG
	T2021-7007
	SG
	Granted
	04-Sep-2003
	 
	 
	110718
	31-Jul-2007
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

Exhibit 10.1

	
													
	03770286.7
	TR
	T2021-7007
	TR
	Granted
	04-Sep-2003
	1534340
	01-Jun-2005
	TR 2012 01650 T4
	16-Nov-2011
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTICS AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	10184884.4
	TR
	T2021-7007
	TR1
	Granted
	04-Sep-2003
	2277551
	26-Jan-2011
	TR 2013 08613 T4
	22-Aug-2013
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	Cerulean Pharma Inc.

	100146937
	TW
	T2021-7007
	T1
	Granted
	05-Sep-2003
	I422379
	11-Jan-2014
	I422379
	11-Jan-2014
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	92124615
	TW
	T2021-7007
	TW
	Granted
	05-Sep-2003
	I366464
	21-Jun-2012
	I366464
	21-Jun-2012
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/769052
	US
	T2021-7007
	030FT
	Granted
	15-Feb-2013
	US-2013-0165405-A1
	27-Jun-2013
	8580244
	12-Nov-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/769019
	US
	T2021-7007
	031FT
	Granted
	15-Feb-2013
	US-2013-0203700-A1
	08-Aug-2013
	8580243
	12-Nov-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/769076
	US
	T2021-7007
	032FT
	Granted
	15-Feb-2013
	US-2013-0156721-A1
	20-Jun-2013
	8603454
	10-Dec-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	14/061868
	US
	T2021-7007
	034
	Granted
	24-Oct-2013
	US-2014-0288023-A1
	25-Sep-2014
	9550860
	24-Jan-2017
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	10/656838
	US
	T2021-7007
	10
	Granted
	05-Sep-2003
	0077595A1
	22-Apr-2004
	7270808
	18-Sep-2007
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	11/881325
	US
	T2021-7007
	20
	Granted
	25-Jul-2007
	US-2008-0058427-A1
	06-Mar-2008
	8110179
	07-Feb-2012
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/421839
	US
	T2021-7007
	21FT
	Granted
	15-Mar-2012
	US-2012-0178711-A1
	12-Jul-2012
	8252276
	28-Aug-2012
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/553376
	US
	T2021-7007
	22
	Granted
	19-Jul-2012
	US-2012-0283214-A1
	08-Nov-2012
	8399431
	19-Mar-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC

	13/553400
	US
	T2021-7007
	23
	Granted
	19-Jul-2012
	US-2012-0289480-A1
	15-Nov-2012
	8389499
	05-Mar-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC

	13/572283
	US
	T2021-7007
	24
	Granted
	10-Aug-2012
	US-2012-0301424-A1
	29-Nov-2012
	8404662
	26-Mar-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC

Exhibit 10.1

	
													
	13/572243
	US
	T2021-7007
	25
	Granted
	10-Aug-2012
	US-2013-0039880-A1
	14-Feb-2013
	8475781
	02-Jul-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC

	13/572294
	US
	T2021-7007
	26
	Granted
	10-Aug-2012
	US-2013-0190450-A1
	25-Jul-2013
	8680202
	25-Mar-2014
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC

	13/739864
	US
	T2021-7007
	27FT
	Granted
	11-Jan-2013
	US-2013-0131013-A1
	23-May-2013
	8518388
	27-Aug-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/739881
	US
	T2021-7007
	28FT
	Granted
	11-Jan-2013
	US-2013-0196945-A1
	01-Aug-2013
	8580242
	12-Nov-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/739896
	US
	T2021-7007
	29FT
	Granted
	11-Jan-2013
	US-2013-0129665-A1
	23-May-2013
	8609081
	17-Dec-2013
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	13/277780
	US
	T2021-7007
	40
	Granted
	20-Oct-2011
	US-2012-0065368-A1
	15-Mar-2012
	8314230
	20-Nov-2012
	CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	2005/01848
	ZA
	T2021-7007
	ZA
	Granted
	04-Sep-2003
	 
	 
	2005/01848
	28-Jun-2006
	CYCLODEXTRIN-BASED POLYMERS FOR DELIVERING THE THERAPEUTIC AGENTS COVALENTLY BOUND THERETO
	CHENG, Jianjun; DAVIS, Mark E.; KHIN, Kay T.
	CERULEAN PHARMA INC.

	14/042996
	US
	T2021-7045
	10
	Published
	01-Oct-2013
	US-2014-0094432-A1
	03-Apr-2014
	 
	 
	METHODS AND SYSTEMS FOR POLYMER PRECIPITATION AND GENERATION OF PARTICLES
	RAMSTACK, J. MichaelExhibit
10.7

 

Forum
Merger Corporation

135
East 57th Street, 8th Floor

New
York, NY 10036

 

December
28, 2016

Forum
Investors I, LLC

135
East 57th Street, 8th Floor

New
York, NY 10036

 

RE: Securities
Subscription Agreement

 

Ladies
and Gentlemen:

 

We
are pleased to accept the offer Forum Investors I, LLC (the “Subscriber” or “you”) has made
to purchase 3,593,750  shares of Class F common stock (the “Shares”), $.0001 par value per share
(the “Class F Common Stock” together with all other classes of Company (as defined below) common
stock, the “Common Stock”), up to 468,750 Shares of which are subject to complete or partial forfeiture by
you if the underwriters of the initial public offering (“IPO”) of Forum Merger Corporation, a Delaware corporation
(the “Company”), do not fully exercise their over-allotment option (the “Over-allotment Option”).
The terms (this “Agreement”) on which the Company is willing to sell the Shares to the Subscriber, and the
Company and the Subscriber’s agreements regarding such Shares, are as follows:

 

1.  Purchase
of Shares. For the sum of $25,000 (the “Purchase Price”), which the Company acknowledges receiving in cash,
the Company hereby sells and issues the Shares to the Subscriber, and the Subscriber hereby purchases the Shares from the Company,
subject to the forfeiture provisions of Section 3 below, on the terms and subject to the conditions set forth in this Agreement.
Concurrently with the Subscriber’s execution of this Agreement, the Company is delivering to the Subscriber a certificate
registered in the Subscriber’s name representing the Shares (the “Original Certificate”), receipt of
which the Subscriber hereby acknowledges.

 

2.  Representations,
Warranties and Agreements.

 

2.1.  Subscriber’s
Representations, Warranties and Agreements. To induce the Company to issue the Shares to the Subscriber, the Subscriber hereby
represents and warrants to the Company and agrees with the Company as follows:

 

2.1.1.  No
Government Recommendation or Approval. The Subscriber understands that no federal or state agency has passed upon or made
any recommendation or endorsement of the offering of the Shares.

 

2.1.2.  No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Subscriber of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the formation and governing documents of the
Subscriber, (ii) any agreement, indenture or instrument to which the Subscriber is a party, (iii) any law, statute, rule or regulation
to which the Subscriber is subject, or (iv) any agreement, order, judgment or decree to which the Subscriber is subject.

 

2.1.3.  Organization
and Authority. The Subscriber is a Delaware limited liability company, validly existing and in good standing under the laws
of Delaware and possesses all requisite power and authority necessary to carry out the transactions contemplated by this Agreement.
Upon execution and delivery by you, this Agreement will be a legal, valid and binding agreement of Subscriber, enforceable against
Subscriber in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, fraudulent
conveyance or similar laws affecting the enforcement of creditors’ rights generally and subject to general principles of
equity (regardless of whether enforcement is sought in a proceeding at law or in equity).

 

    	 		 

     

    

 

2.1.4.  Experience,
Financial Capability and Suitability. Subscriber is: (i) sophisticated in financial matters and is able to evaluate the risks
and benefits of the investment in the Shares and (ii) able to bear the economic risk of its investment in the Shares for an indefinite
period of time because the Shares have not been registered under the Securities Act (as defined below) and therefore cannot be
resold unless subsequently registered under the Securities Act or an exemption from such registration is available. Subscriber
is capable of evaluating the merits and risks of its investment in the Company and has the capacity to protect its own interests.
Subscriber must bear the economic risk of this investment until the Shares are sold pursuant to: (x) an effective registration
statement under the Securities Act or (y) an exemption from registration available with respect to such sale. Subscriber is able
to bear the economic risks of an investment in the Shares and to afford a complete loss of Subscriber’s investment in the
Shares.

 

2.1.5.  Access
to Information; Independent Investigation. Prior to the execution of this Agreement, the Subscriber has had the opportunity
to ask questions of and receive answers from representatives of the Company concerning an investment in the Company, as well as
the finances, operations, business and prospects of the Company, and the opportunity to obtain additional information to verify
the accuracy of all information so obtained. In determining whether to make this investment, Subscriber has relied solely on Subscriber’s
own knowledge and understanding of the Company and its business based upon Subscriber’s own due diligence investigation
and the information furnished pursuant to this paragraph. Subscriber understands that no person has been authorized to give any
information or to make any representations which were not furnished pursuant to this Section 2 and Subscriber has not relied on
any other representations or information in making its investment decision, whether written or oral, relating to the Company,
its operations or its prospects.

 

2.1.6.  Regulation
D Offering. Subscriber represents that it is an “accredited investor” as such term is defined in Rule 501(a) of
Regulation D under the Securities Act of 1933, as amended (the “Securities Act”) and acknowledges the sale
contemplated hereby is being made in reliance on a private placement exemption applicable to “accredited investors”
or similar exemptions under federal and state law.

 

2.1.7.  Investment
Purposes. The Subscriber is purchasing the Shares solely for investment purposes, for the Subscriber’s own account and
not for the account or benefit of any other person, and not with a view towards the distribution or dissemination thereof. The
Subscriber did not enter into this Agreement as a result of any general solicitation or general advertising within the meaning
of Rule 502 of Regulation D under the Securities Act.

 

2.1.8.  Restrictions
on Transfer; Shell Company. Subscriber understands the Shares are being offered in a transaction not involving a public offering
within the meaning of the Securities Act.  Subscriber understands the Shares will be “restricted securities”
as defined in Rule 144(a)(3) under the Securities Act and Subscriber understands that the certificate representing the Shares
will contain a legend in respect of such restrictions. If in the future the Subscriber decides to offer, resell, pledge or otherwise
transfer the Shares, such Shares may be offered, resold, pledged or otherwise transferred only in accordance with the provisions
of Section 5.1 hereof. Subscriber agrees that if any transfer of its Shares or any interest therein is proposed to be made, as
a condition precedent to any such transfer, Subscriber may be required to deliver to the Company an opinion of counsel satisfactory
to the Company. Absent registration or an exemption, the Subscriber agrees not to resell the Shares. Subscriber further acknowledges
that because the Company is a shell company, Rule 144 may not be available to the Subscriber for the resale of the Shares until
one year following consummation of the initial business combination of the Company, despite technical compliance with the certain
requirements of Rule 144 and the release or waiver of any contractual transfer restrictions.

 

2.1.9.  No
Governmental Consents. No governmental, administrative or other third party consents or approvals are required, necessary
or appropriate on the part of Subscriber in connection with the transactions contemplated by this Agreement.

 

2.2.  Company’s
Representations, Warranties and Agreements. To induce the Subscriber to purchase the Shares, the Company hereby represents
and warrants to the Subscriber and agrees with the Subscriber as follows:

 

2.2.1.  Organization
and Corporate Power. The Company is a Delaware corporation and is qualified to do business in every jurisdiction in which
the failure to so qualify would reasonably be expected to have a material adverse effect on the financial condition, operating
results or assets of the Company. The Company possesses all requisite corporate power and authority necessary to carry out the
transactions contemplated by this Agreement.

 

2.2.2.  No
Conflicts. The execution, delivery and performance of this Agreement and the consummation by the Company of the transactions
contemplated hereby do not violate, conflict with or constitute a default under (i) the Certificate of Incorporation or Bylaws
of the Company, (ii) any agreement, indenture or instrument to which the Company is a party, (iii) any law, statute, rule or regulation
to which the Company is subject, or (iv) any agreement, order, judgment or decree to which the Company is subject.

 

    	 	2	 

     

    

 

2.2.3.  Title
to Securities. Upon issuance in accordance with, and payment pursuant to, the terms hereof, the Shares will be duly and validly
issued, fully paid and nonassessable. Upon issuance in accordance with, and payment pursuant to, the terms hereof the Subscriber
will have or receive good title to the Shares, free and clear of all liens, claims and encumbrances of any kind, other than (a)
transfer restrictions hereunder and other agreements to which the Shares may be subject which have been notified to the Subscriber
in writing, (b) transfer restrictions under federal and state securities laws, and (c) liens, claims or encumbrances imposed due
to the actions of the Subscriber.

 

2.2.4.  No
Adverse Actions. There are no actions, suits, investigations or proceedings pending, threatened against or affecting the Company
which: (i) seek to restrain, enjoin, prevent the consummation of or otherwise affect the transactions contemplated by this Agreement
or (ii) question the validity or legality of any transactions or seek to recover damages or to obtain other relief in connection
with any transactions.

 

3.  Forfeiture
of Shares.

 

3.1. Partial
or No Exercise of the Over-allotment Option. In the event the Over-allotment Option granted to the representative of the underwriters
of the IPO is not exercised in full, the Subscriber acknowledges and agrees that it shall forfeit any and all rights to such number
of Shares (up to an aggregate of 468,750 Shares and pro rata based upon the percentage of the Over-allotment Option exercised)
such that immediately following such forfeiture, the Subscriber (and all other initial stockholders prior to the IPO, if any)
will own an aggregate number of Shares (not including Shares issuable upon exercise of any warrants or any Common Stock purchased
by Subscriber in the IPO or in the aftermarket, any Shares underlying units to be issued in a private placement at the time of
the IPO or any Shares to be issued to the underwriters at the time of the IPO) equal to 20% of the issued and outstanding Common
Stock immediately following the IPO.

 

3.2.  Termination
of Rights as Stockholder. If any of the Shares are forfeited in accordance with this Section 3, then after such time the Subscriber
(or successor in interest), shall no longer have any rights as a holder of such Shares, and the Company shall take such action
as is appropriate to cancel such Shares. 

 

3.3.  Share
Certificates. In the event an adjustment to the Original Certificate is required pursuant to this Section 3, then the Subscriber
shall return such Original Certificate to the Company or its designated agent as soon as practicable upon its receipt of notice
from the Company advising Subscriber of such adjustment, following which a new certificate (the “New Certificate”)
shall be issued in such amount representing the adjusted number of Shares held by the Subscriber. The New Certificate shall be
returned to the Subscriber as soon as practicable.

 

4.  Waiver
of Liquidation Distributions; Redemption Rights. In connection with the Shares purchased pursuant to this Agreement, the Subscriber
hereby waives any and all right, title, interest or claim of any kind in or to any distributions by the Company from the trust
account which will be established for the benefit of the Company’s public stockholders and into which substantially all
of the proceeds of the IPO will be deposited (the “Trust Account”), in the event of a liquidation of the Company
upon the Company’s failure to timely complete an initial business combination. For purposes of clarity, in the event the
Subscriber purchases Common Stock in the IPO or in the aftermarket, any additional Common Stock so purchased shall be eligible
to receive any liquidating distributions by the Company. However, in no event will the Subscriber have the right to redeem any
Shares into funds held in the Trust Account upon the successful completion of an initial business combination.

 

5.  Restrictions
on Transfer.

 

5.1.  Securities
Law Restrictions. In addition to any restrictions to be contained in that certain letter agreement (commonly known as an “Insider
Letter”) to be dated as of the closing of the IPO by and between Subscriber and the Company, Subscriber agrees not to
sell, transfer, pledge, hypothecate or otherwise dispose of all or any part of the Shares unless, prior thereto (a) a registration
statement on the appropriate form under the Securities Act and applicable state securities laws with respect to the Shares proposed
to be transferred shall then be effective or (b) the Company has received an opinion from counsel reasonably satisfactory to the
Company, that such registration is not required because such transaction is exempt from registration under the Securities Act
and the rules promulgated by the Securities and Exchange Commission thereunder and with all applicable state securities laws.

 

    	 	3	 

     

    

 

5.2.  Lock-up.  Subscriber
acknowledges that the Shares will be placed into an escrow account maintained in New York, New York by Continental Stock
Transfer & Trust Company (“CST”), acting as escrow agent, and shall be subject to lock-up provisions (the
“Lock-up”) contained in that certain stock escrow agreement (the “Escrow Agreement”) to be
entered into as of, or prior to, the closing of the IPO by and between Subscriber and CST. Pursuant to the Escrow Agreement,
Subscriber will agree not to sell, transfer, pledge, hypothecate or otherwise dispose of (i) all or any part of 50% the
Shares until the earlier to occur of: (A) one year after the completion of the Company’s initial business combination
or (B) the date on which the last sale price of the Common Stock equals or exceeds $12.50 per share (as adjusted for stock
splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day
period,  and all or any part of the remaining 50% the Shares until one year after the completion of the
Company’s initial business combination; notwithstanding the foregoing, if the Company consummates a subsequent
liquidation, merger, stock exchange or other similar transaction after its initial business combination that results in all
of its stockholders having the right to exchange their shares of Common Stock for cash, securities or other property, the
foregoing restrictions will immediately expire so that the Subscriber may participate in such
transaction.   

 

5.3.  Restrictive
Legends. All certificates representing the Shares shall have endorsed thereon legends substantially as follows:

 

“THE
SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS
AND NEITHER THE SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER SUCH ACT OR SUCH LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND
SUCH LAWS WHICH, IN THE OPINION OF COUNSEL, IS AVAILABLE.”

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO AN ESCROW AGREEMENT AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED
OR OTHERWISE DISPOSED DURING THE TERM OF SUCH AGREEMENT.”

 

5.4.  Additional
Shares or Substituted Securities. In the event of the declaration of a stock dividend, the declaration of a special dividend
payable in a form other than Common Stock, a spin-off, a stock split, an adjustment in conversion ratio, a recapitalization or
a similar transaction affecting the Company’s outstanding Common Stock without receipt of consideration, any new, substituted
or additional securities or other property which are by reason of such transaction distributed with respect to any Shares subject
to this Section 5 or into which such Shares thereby become convertible shall immediately be subject to this Section 5 and Section
3. Appropriate adjustments to reflect the distribution of such securities or property shall be made to the number or class of
Shares subject to this Section 5 and Section 3.

 

5.5.  Registration
Rights. Subscriber acknowledges that the Shares are being purchased pursuant to an exemption from the registration requirements
of the Securities Act and will become freely tradable only after certain conditions are met or they are registered pursuant to
a Registration Rights Agreement to be entered into with the Company prior to the closing of the IPO.

 

6.  Other
Agreements.

 

6.1.  Further
Assurances. Subscriber agrees to execute such further instruments and to take such further action as may reasonably be necessary
to carry out the intent of this Agreement.

 

6.2.  Notices.
All notices, statements or other documents which are required or contemplated by this Agreement shall be in writing and delivered:
(i) personally or sent by first class registered or certified mail, overnight courier service or facsimile or electronic transmission
to the address designated in writing, (ii) by facsimile to the number most recently provided to such party or such other address
or fax number as may be designated in writing by such party and (iii) by electronic mail, to the electronic mail address most
recently provided to such party or such other electronic mail address as may be designated in writing by such party. Any notice
or other communication so transmitted shall be deemed to have been given on the day of delivery, if delivered personally, on the
business day following receipt of written confirmation, if sent by facsimile or electronic transmission, one (1) business day
after delivery to an overnight courier service or five (5) days after mailing if sent by mail.

 

    	 	4	 

     

    

 

6.3.  Entire
Agreement. This Agreement, together with that certain Insider Letter to be entered into between Subscriber and the Company,
substantially in the form to be filed as an exhibit to the Registration Statement, embodies the entire agreement and understanding
between the Subscriber and the Company with respect to the subject matter hereof and supersedes all prior oral or written agreements
and understandings relating to the subject matter hereof. No statement, representation, warranty, covenant or agreement of any
kind not expressly set forth in this Agreement shall affect, or be used to interpret, change or restrict, the express terms and
provisions of this Agreement.

 

6.4.  Modifications
and Amendments. The terms and provisions of this Agreement may be modified or amended only by written agreement executed by
all parties hereto.

 

6.5.  Waivers
and Consents. The terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only
by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall
be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether
or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it
was given, and shall not constitute a continuing waiver or consent.

 

6.6.  Assignment.
The rights and obligations under this Agreement may not be assigned by either party hereto without the prior written consent of
the other party.

 

6.7.  Benefit.
All statements, representations, warranties, covenants and agreements in this Agreement shall be binding on the parties hereto
and shall inure to the benefit of the respective successors and permitted assigns of each party hereto. Nothing in this Agreement
shall be construed to create any rights or obligations except among the parties hereto, and no person or entity shall be regarded
as a third-party beneficiary of this Agreement.

 

6.8.  Governing
Law. This Agreement and the rights and obligations of the parties hereunder shall be construed in accordance with and governed
by the laws of New York applicable to contracts wholly performed within the borders of such state, without giving effect to the
conflict of law principles thereof.

 

6.9.  Severability.
In the event that any court of competent jurisdiction shall determine that any provision, or any portion thereof, contained in
this Agreement shall be unreasonable or unenforceable in any respect, then such provision shall be deemed limited to the extent
that such court deems it reasonable and enforceable, and as so limited shall remain in full force and effect. In the event that
such court shall deem any such provision, or portion thereof, wholly unenforceable, the remaining provisions of this Agreement
shall nevertheless remain in full force and effect.

 

6.10.  No
Waiver of Rights, Powers and Remedies. No failure or delay by a party hereto in exercising any right, power or remedy under
this Agreement, and no course of dealing between the parties hereto, shall operate as a waiver of any such right, power or remedy
of such party. No single or partial exercise of any right, power or remedy under this Agreement by a party hereto, nor any abandonment
or discontinuance of steps to enforce any such right, power or remedy, shall preclude such party from any other or further exercise
thereof or the exercise of any other right, power or remedy hereunder. The election of any remedy by a party hereto shall not
constitute a waiver of the right of such party to pursue other available remedies. No notice to or demand on a party not expressly
required under this Agreement shall entitle the party receiving such notice or demand to any other or further notice or demand
in similar or other circumstances or constitute a waiver of the rights of the party giving such notice or demand to any other
or further action in any circumstances without such notice or demand.

 

    	 	5	 

     

    

 

6.11.  Survival
of Representations and Warranties. All representations and warranties made by the parties hereto in this Agreement or in any
other agreement, certificate or instrument provided for or contemplated hereby, shall survive the execution and delivery hereof
and any investigations made by or on behalf of the parties.

 

6.12.  No
Broker or Finder. Each of the parties hereto represents and warrants to the other that no broker, finder or other financial
consultant has acted on its behalf in connection with this Agreement or the transactions contemplated hereby in such a way as
to create any liability on the other. Each of the parties hereto agrees to indemnify and hold the other harmless from any claim
or demand for commission or other compensation by any broker, finder, financial consultant or similar agent claiming to have been
employed by or on behalf of such party and to bear the cost of legal expenses incurred in defending against any such claim.

 

6.13.  Headings
and Captions. The headings and captions of the various sections of this Agreement are for convenience of reference only and
shall in no way modify or affect the meaning or construction of any of the terms or provisions hereof.

 

6.14.  Counterparts.
This Agreement may be executed in one or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission
or any other form of electronic delivery, such signature shall create a valid and binding obligation of the party executing (or
on whose behalf such signature is executed) with the same force and effect as if such signature page were an original thereof.

 

6.15.  Construction.
The words “include,” “includes,” and “including” will be deemed to be
followed by “without limitation.” Pronouns in masculine, feminine, and neuter genders will be construed to
include any other gender, and words in the singular form will be construed to include the plural and vice versa, unless the context
otherwise requires. The words “this Agreement,” “herein,” “hereof,” “hereby,”
“hereunder,” and words of similar import refer to this Agreement as a whole and not to any particular section
unless expressly so limited. The parties hereto intend that each representation, warranty, and covenant contained herein will
have independent significance. If any party hereto has breached any representation, warranty, or covenant contained herein in
any respect, the fact that there exists another representation, warranty or covenant relating to the same subject matter (regardless
of the relative levels of specificity) which such party hereto has not breached will not detract from or mitigate the fact that
such party hereto is in breach of the first representation, warranty, or covenant.

 

6.16. Mutual
Drafting. This Agreement is the joint product of the Subscriber and the Company and each provision hereof has been subject
to the mutual consultation, negotiation and agreement of such parties and shall not be construed for or against any party hereto.

 

7.  Voting
and Redemption of Shares. Subscriber agrees to vote the Shares in favor of an initial business combination that the Company
negotiates and submits for approval to the Company’s stockholders and shall not seek redemption with respect to such Shares.
Additionally, the Subscriber agrees not to redeem any Shares in connection with a redemption or tender offer presented to the
Company’s stockholders in connection with an initial business combination negotiated by the Company.

 

8.  Indemnification.
Each party shall indemnify the other against any loss, cost or damages (including reasonable attorneys’ fees and expenses)
incurred as a result of such party’s breach of any representation, warranty, covenant or agreement in this Agreement.

 

[Signature
Page Follows]

 

    	 	6	 

     

    

 

If
the foregoing accurately sets forth our understanding and agreement, please sign the enclosed copy of this Agreement and return
it to us.

 

	 	Very
    truly yours,  
	 	 
	 	FORUM
    MERGER CORPORATION
	 	 
	 	By:	                       
	 	Name:	 
	 	Title:	 

  

Accepted
and agreed this 28th day of December, 2016

 

	FORUM
        INVESTORS I, LLC

         

        

        
	 
	By:	FORUM CAPITAL MANAGEMENT, LLC,	 
	 	its
        managing member	 
	 	 	 
	By:	          	 
	Name:	 	 
	Title:	 	 

 

 

7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]